None listed
Conditions
Interventions
Procedure/Surgery : A second pretreatment evaluation is performed using a microballoon catheter before TARE, and the results are compared with those obtained from the initial evaluation using a conven
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults aged 19 years or older. 2. Patients who have provided written informed consent. 3. Patients with hepatocellular carcinoma (HCC) diagnosed according to the AASLD criteria and at least one of the following: i. Contrast-enhanced magnetic resonance imaging (MRI) demonstrating arterial phase hyperenhancement and washout in at least one solid hepatic lesion measuring >1 cm. ii. Contrast-enhanced computed tomography (CT) demonstrating arterial phase hyperenhancement and washout in at least one solid hepatic lesion measuring >1 cm. iii. Histopathologic confirmation for lesions with atypical imaging features. 4. Patients diagnosed with intrahepatic cholangiocarcinoma (ICC) or liver metastases on CT or MRI. 5. Treatment-naïve patients with no prior treatment for liver malignancy. 6. Patients with Child–Pugh class A or B liver function. 7. No restrictions on tumor size or number.
Exclusion criteria
Exclusion criteria: 1. Patients younger than 19 years of age. 2. Patients with chronic kidney disease (CKD) stage 4 or 5. 3. Patients who have received prior treatment for liver cancer, including radiofrequency ablation, chemotherapy, or radiotherapy. 4. Pregnant or breastfeeding women, and women of childbearing potential who are not using effective contraception. 5. Patients with extrahepatic metastasis of liver cancer. 6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status >2. 7. Patients with Child–Pugh class C liver function. 8. Patients with active gastrointestinal bleeding. 9. Patients with evidence of uncorrectable bleeding diathesis. 10. Patients with medically uncontrolled hepatic encephalopathy. 11. Patients with medically uncontrolled ascites. 12. Patients with contraindications to MRI or CT (e.g., metallic implants). 13. Patients with hypersensitivity to contrast media that cannot be adequately managed with prophylaxis. 14. Patients with contraindications to angiography. 15. Patients with contraindications to transarterial radioembolization (TARE), including: • Extensive portosystemic shunting. • Hepatofugal portal venous flow. • Serum bilirubin >3.0 mg/dL. • Serum creatinine >2.0 mg/dL. • Any other condition considered exclusionary by the investigator. • Uncorrectable coagulopathy. 16. Patients who, in the opinion of the investigator, are considered unsuitable for participation in this clinical trial for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor-to-normal liver ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| lung shunt fraction;final radiation dose | — |
Countries
Korea, Republic of
Contacts
Public ContactGun Ha Kim
Asan Medical Center
Outcome results
None listed